WuXi AppTec (Stock Code: 02359) has obtained a preliminary injunction from the U.S. District Court for the District of Columbia, temporarily blocking the U.S. Department of Defense (DoD) from enforcing the company’s inclusion on the 1260H list.

The company initiated litigation against the DoD on 11 June 2026 and filed for a preliminary injunction on 29 June 2026. A court hearing was held on 22 July 2026, culminating in the 7 August 2026 ruling that suspends any immediate adverse effects of the 1260H designation during the ongoing judicial review.

Management stated that all operations remain fully functional and the company continues to serve its customers and patients. The board reiterated its objection to the “erroneous” designation and expressed confidence in a favorable outcome following an objective legal review.

Shareholders and potential investors are advised to exercise caution when dealing in WuXi AppTec’s shares.

The board currently comprises four executive directors (Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang), two non-executive directors (Mr. Xiaomeng Tong and Dr. Yibing Wu) and five independent non-executive directors (Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng).

Date of announcement: 9 August 2026.